Loading...

FDA Approves Controversial Alzheimer’s Drug Despite Potential Harm

June 7, 2021 by Reece Nations
FDA Approves Controversial Alzheimer’s Drug Despite Potential Harm
In this 2019 photo provided by Biogen, a researcher works on the development of the medication aducanumab in Cambridge, Mass. On Monday, June 7, 2021, the Food and Drug Administration approved aducanumab, the first new drug for Alzheimer’s disease in nearly 20 years, disregarding warnings from independent advisers that the much-debated treatment hasn’t been shown to help slow the brain-destroying disease. (Biogen via AP)

SILVER SPRING, Md. — The Food and Drug Administration on Monday granted its approval to aducanumab, an Alzheimer’s treatment developed by Biogen for use in patients, despite mixed clinical trial results for the drug. 

Prescribed under the brand name “Aduhelm,” the treatment is given intravenously and is meant to remove protein deposits from the brains of patients in the early stages of Alzheimer’s. The proteins are known to cause loss of memory and physical control over one’s body functions.

The effects of the drug were studied in two clinical trials — only one of which deemed Aduhelm as an effective treatment. Prior to its approval, experts on the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee concluded that it was unreasonable to maintain the clinical benefit of one successful trial as the primary evidence supporting its approval.

“We are well-aware of the attention surrounding this approval,” Patrizia Cavazzoni, director of the FDA’s Center for Drug Evaluation and Research, said in a written statement. “We understand that Aduhelm has garnered the attention of the press, the Alzheimer’s patient community, our elected officials, and other interested stakeholders. With a treatment for a serious, life-threatening disease in the balance, it makes sense that so many people were following the outcome of this review.”

Cavazzoni continued, “Further, the data included in the applicant’s submission were highly complex and left residual uncertainties regarding clinical benefit. There has been considerable public debate on whether Aduhelm should be approved. As is often the case when it comes to interpreting scientific data, the expert community has offered differing perspectives.”

In all of its evaluations, the FDA noted Aduhelm “consistently and very convincingly” led to a reduction in the level of amyloid plaques in patient’s brains on a “dose- and time-dependent” basis. Ultimately, the administration concluded the drug satisfied the standards of its “Accelerated Approval” pathway and was likely to produce clinical benefit.

Roughly 40% of trial participants experienced brain bleeding or swelling after receiving high doses of the drug, according to study results published by Biogen. Although most participants were either asymptomatic or experienced only headaches, dizziness or nausea, the effects of the drug caused 6% of high-dose recipients to withdraw from the study.

“We ultimately decided to use the Accelerated Approval pathway — a pathway intended to provide earlier access to potentially valuable therapies for patients with serious diseases where there is an unmet need, and where there is an expectation of clinical benefit despite some residual uncertainty regarding that benefit,” Cavazzoni continued in the FDA’s statement. “In determining that the application met the requirements for Accelerated Approval, the Agency concluded that the benefits of Aduhelm for patients with Alzheimer’s disease outweighed the risks of the therapy.”

The drug will now undergo a post-market study to determine its widespread effectiveness as an Alzheimer’s treatment. If the “Phase 4 trial” fails to demonstrate its effectiveness or leads to adverse health effects in patients, the FDA could subsequently rescind its approval — although it is not required by law.

Aduhelm is the first new Alzheimer’s treatment approved by the FDA since 2003. Roughly six million Americans and 30 million people worldwide have Alzheimer’s, according to analysis by the Alzheimer’s Association. Further, the number of new cases of Alzheimer’s and other dementias is expected to double annually by 2050.

“The consequences of FDA approval are as disturbing as they are vast,” Jason Karlawish, professor of Medicine and Medical Ethics and Senior Fellow of the Center for Bioethics at the University of Pennsylvania, wrote in an op-ed for Stat News. “Around two million Americans could be prescribed aducanumab, at an estimated cost that ranges from $20,000 to $50,000 per person per year. Biogen claims the benefits of slowing declines in cognition and day-to-day function are worth this price. I think the company is wrong, and I agree with the analyses by the Institute for Clinical and Economic Review; the data to make this case are murky and, even if they were clear, the drug’s benefits are ambiguous at best and not worth this cost. Putting it on the market will stress Medicare’s resources.”

In The News

Health

Voting

Health

January 14, 2022
by Dan McCue
White House Announces Plans to Distribute Home COVID Tests

WASHINGTON — Beginning Jan. 19, Americans will be able to order free at-home COVID-19 tests online from the federal government,... Read More

WASHINGTON — Beginning Jan. 19, Americans will be able to order free at-home COVID-19 tests online from the federal government, a senior White House official announced Friday afternoon. In the early going of the new program, individuals will be limited to four free tests per residential... Read More

Mask Rules Get Tighter in Europe in Winter's COVID-19 Wave

ROME (AP) — To mask or not to mask is a question Italy settled early in the COVID-19 outbreak with... Read More

ROME (AP) — To mask or not to mask is a question Italy settled early in the COVID-19 outbreak with a vigorous “yes." Now the onetime epicenter of the pandemic in Europe hopes even stricter mask rules will help it beat the latest infection surge. Other... Read More

January 12, 2022
by Reece Nations
House Rules Committee Rejects G.I. Bill Education Benefits for Vaccine Refusal

WASHINGTON — The House Rules Committee on Monday rejected an amendment to the Guard and Reserve G.I. Bill Parity Act... Read More

WASHINGTON — The House Rules Committee on Monday rejected an amendment to the Guard and Reserve G.I. Bill Parity Act that would guarantee Armed Services members discharged for refusing the COVID-19 vaccine are eligible for G.I. Bill education benefits. The Guard and Reserve G.I. Bill Parity... Read More

January 12, 2022
by Alexa Hornbeck
Reliability of Antigen Rapid Tests in Detecting Early Omicron Questioned

WASHINGTON — Beginning Jan. 15, private health insurers will be required to cover the cost of home testing kits despite... Read More

WASHINGTON — Beginning Jan. 15, private health insurers will be required to cover the cost of home testing kits despite recent concerns from elected officials and researchers over the reliability and availability of rapid antigen testing. “I’ve heard from so many people who are waiting in... Read More

January 12, 2022
by Alexa Hornbeck
COVID Pills Show Promise for Combating Severe Infection

Pfizer’s Paxlovid is the first pill treatment to combat severe COVID-19 infection, and new figures from Israel’s Ministry of Health... Read More

Pfizer’s Paxlovid is the first pill treatment to combat severe COVID-19 infection, and new figures from Israel’s Ministry of Health show the pill may hold promise in saving lives. Shortly before Christmas Day, Paxlovid was authorized for at-home treatment of high-risk COVID-19 infections in patients over... Read More

January 12, 2022
by Alexa Hornbeck
Researchers Develop mRNA-based Lyme Disease Vaccine

Yale researchers recently developed an mRNA-based Lyme disease vaccine capable of targeting antigens in tick saliva to prevent their ability... Read More

Yale researchers recently developed an mRNA-based Lyme disease vaccine capable of targeting antigens in tick saliva to prevent their ability to transmit pathogens.  According to the CDC, nearly half a million people in the U.S. are diagnosed with Lyme Disease every year. The ailment is most... Read More

News From The Well
Exit mobile version